CyTuVax
CyTuVax is a clinical stage vaccine company dedicated to developing solutions for high medical need, including therapeutic vaccines against cancer and prophylactic vaccines against viral and bacterial pathogens. Their innovative adjuvant platform technology induces powerful immune responses, enhances vaccine effectiveness, and reduces the number of injections needed. The company collaborates with top European research institutions and has demonstrated the strength of its technology in clinical trials, including a Phase 2 study for hepatitis B non-responders. CyTuVax's mission is centered on patient needs, leveraging depot-attached cytokines as immune stimulators to create effective vaccines.
Industries
Nr. of Employees
small (1-50)
Products
Hepatitis B vaccine candidate for non-responders (HBAI20)
Clinical-stage hepatitis B vaccine candidate formulated with a depot cytokine-aggregate adjuvant aimed at inducing seroprotection in individuals who did not respond to prior standard hepatitis B vaccination.
Personalized tumor vaccine platform
A platform approach for personalized cancer vaccines combining depot cytokine-aggregate adjuvants with tumor-specific antigens delivered as mRNA, autologous tumor cells, or overlapping long peptides (OLPs).
Hepatitis B vaccine candidate for non-responders (HBAI20)
Clinical-stage hepatitis B vaccine candidate formulated with a depot cytokine-aggregate adjuvant aimed at inducing seroprotection in individuals who did not respond to prior standard hepatitis B vaccination.
Personalized tumor vaccine platform
A platform approach for personalized cancer vaccines combining depot cytokine-aggregate adjuvants with tumor-specific antigens delivered as mRNA, autologous tumor cells, or overlapping long peptides (OLPs).
Services
Clinical trial collaboration and execution
Design and conduct of randomized, multi-site clinical trials for vaccine candidates, including clinical site partnerships and trial registration.
Vaccine platform development and preclinical testing
Development and preclinical evaluation of vaccine candidates using depot-formulated cytokine-aggregate adjuvants combined with mRNA, tumor cells, or peptides.
Clinical trial collaboration and execution
Design and conduct of randomized, multi-site clinical trials for vaccine candidates, including clinical site partnerships and trial registration.
Vaccine platform development and preclinical testing
Development and preclinical evaluation of vaccine candidates using depot-formulated cytokine-aggregate adjuvants combined with mRNA, tumor cells, or peptides.
Expertise Areas
- Vaccine platform development
- Cancer immunotherapy
- Clinical trial management and execution
- Adjuvant formulation and depot delivery
Key Technologies
- Cytokine-aggregate adjuvant technology
- mRNA-based vaccine antigens
- Autologous tumor cell vaccines
- Overlapping long peptide (OLP) vaccines